|Home | About | Journals | Submit | Contact Us | Français|
MHC class II transactivator (CIITA), a co-activator that controls MHC class II (MHC II) transcription, functions as the master regulator of MHC II expression. Persistent activity of the CIITA type III promoter (pIII), one of the four potential promoters of this gene, is responsible for constitutive expression of MHC II by B lymphocytes. In addition, IFN-γ induces expression of CIITA in these cells through the type IV promoter (pIV). Positive regulatory domain 1-binding factor 1 (PRDI-BF1), called B lymphocyte-induced maturation protein 1 (Blimp-1) in mice, represses the expression of CIITA pIII in plasma and multiple myeloma cells. To investigate regulation of CIITA pIV expression by PRDI-BF1 in the B lymphocyte lineage, protein/DNA binding studies, and functional promoter analyses were performed. PRDI-BF1 bound to the IRF-E site in CIITA pIV. Ectopic expression of either PRDI-BF1 or Blimp-1 repressed this promoter in B lymphocytes. In vitro binding and functional analyses of CIITA pIV demonstrated that the IFN regulatory factor-element (IRF-E) is the target of this repression. In vivo genomic footprint analysis demonstrated protein binding at the IRF-E site of CIITA pIV in U266 myeloma cells, which express PRDI-BF1. PRDI-BF1β, a truncated form of PRDI-BF1 that is co-expressed in myeloma cells, also bound to the IRF-E site and repressed CIITA pIV. These findings demonstrate for the first time that, in addition to silencing expression of CIITA pIII in B lymphocytes, PRDI-BF1 is capable of binding and suppressing CIITA pIV.
The MHC class II transactivator (CIITA) is the primary regulator of both constitutive and inducible expression of MHC class II (MHC II) (Steimle et al., 1993; Steimle et al., 1994; Chang et al., 1994). Interacting with specific DNA-binding and basal transcription factors in the cell nucleus, CIITA acts as a transcriptional co-activator of MHC II genes (Zika and Ting, 2005; Harton and Ting, 2000). To a lesser degree the expression of other genes that function in antigen presentation by MHC II, like invariant chain and DM, are also regulated by CIITA (Chang and Flavell, 1995; Kern et al., 1995; Chin et al., 1997; Westerheide et al., 1997; Nagarajan et al., 2002). As such, CIITA serves as an essential master switch for MHC II antigen presentation and immune responses.
The human CIITA gene, MHC2TA, is regulated primarily at the level of transcription utilizing at least three of four distinct promoters, designated from 5′ to 3′ upstream of the CIITA gene as promoter I–IV (Landmann et al., 2001; Ting and Trowsdale, 2002). Through the use of these multiple promoters, CIITA is regulated in a complex and cell-type specific manner. The CIITA type I promoter (pI) is primarily expressed in myeloid dendritic cells and macrophages cells (Muhlethaler-Mottet et al., 1997; Landmann et al., 2001; Pai et al., 2002). The function of the type II promoter is presently unknown. It is not conserved across species and is only minimally active in human cells (Muhlethaler-Mottet et al., 1997). CIITA type III promoter (pIII) expression is important in B lymphocytes where it is constitutively active, but it can also be induced by IFN-γ stimulation in a number of different cell types (Nikcevich et al., 1997; Piskurich et al., 1999; Soos et al., 2001; Pai et al., 2002; van der Stoep et al., 2002; Nagabhushanam et al., 2003). The CIITA type IV promoter (pIV) is responsive to IFN-γ in many non-professional antigen-presenting cell types and is considered to be the main IFN-γ-inducible promoter of CIITA (Muhlethaler-Mottet et al., 1998; Piskurich et al., 1998; Dong et al., 1999; Piskurich et al., 1999; Soos et al., 2001; Waldburger et al., 2001). Importantly, we have recently shown that CIITA pIV is also active and regulated by IFN-γ in B lymphocytes (Piskurich et al., 2005).
CIITA pIV has multiple, highly conserved upstream regulatory elements that control its activity. These include an IFN-γ activation factor DNA-binding sequence (GAS) element, E-Box, and IFN regulatory factor-element (IRF-E) (Muhlethaler-Mottet et al., 1997; Muhlethaler-Mottet et al., 1998). Several mechanisms have been described for CIITA pIV activation by IFN-γ, including the binding of STAT1 to the GAS site, the binding of the IFN regulatory factors (IRFs) IRF-1 and IRF-2 to the IRF-E, and the binding of USF-1 to the E box (Muhlethaler-Mottet et al., 1998; Piskurich et al., 1999; Xi et al., 1999; Morris et al., 2002; Xi and Blanck, 2003).
Positive regulatory domain I-binding factor 1(PRDI-BF1), called B lymphocyte-induced maturation protein 1 (Blimp-1) in mice, acts as a transcriptional repressor in a variety of cell types (Kakkis and Calame, 1987; Kakkis et al., 1989; Lin et al., 1997). This repressor plays an important role in B lymphocyte development since it triggers the terminal differentiation of B cells into plasma cells (Turner, Jr. et al., 1994; Shaffer et al., 2002; Shapiro-Shelef et al., 2003). A recent report indicates that during plasmacytic differentiation, this repressor might regulate more than 250 genes either directly or indirectly (Shaffer et al., 2002). However, only a few direct targets for PRDI-BF1/Blimp-1 have been identified so far including IFN-β, c-Myc, spi-B, Id3 and Pax-5 (Kelly et al., 1991; Lin et al., 1997; Lin et al., 2002; Shaffer et al., 2002). In addition, we have shown that PRDI-BF1/Blimp-1 suppresses constitutive expression of MHC II by repressing CIITA pIII in B lymphocytes and multiple myeloma cells (Piskurich et al., 2000; Ghosh et al., 2001). Although only a handful of direct targets of repression have been verified, a recent report indicates that the DNA binding site for Blimp-1 resembles sites recognized by IRF-1 and IRF-2 (Kuo and Calame, 2004). Since the CIITA pIV promoter contains an IRF-E sequence that binds both IRF-1 and IRF-2, it represents a good candidate for regulation by PRDI-BF1/Blimp-1 (Muhlethaler-Mottet et al., 1998; Piskurich et al., 1999; Xi et al., 1999; Morris et al., 2002; Xi and Blanck, 2003). We have recently shown that this promoter is active and regulated by IFN-γ in B lymphocytes (Piskurich et al., 2006).
The purpose of this study is to investigate the ability of PRDI-BF1 to regulate the CIITA type IV promoter in cells of the B lymphocyte lineage. This is important since CIITA expression controls the ability of B lymphocytes to present antigen. We demonstrate for the first time that besides silencing constitutive CIITA expression by repressing the CIITA type III promoter, PRDI-BF1/Blimp-1 also suppresses the basal and inducible activity of the CIITA type IV promoter in these cells. These studies provide new evidence that PRDI-BF1 is an attractive target for the development of therapies to increase the ability of the immune system to recognize B cell neoplasms, especially multiple myeloma.
The human B lymphocyte cell lines, Raji and CA46, and the human myeloma cell lines, U266 and NCI-H929, were grown according to American Type Culture Collection specifications in RPMI 1640 with 10% fetal calf serum, 2mM L-glutamine, and 100 U/ml penicillin and streptomycin.
The human CIITA gene (MHC2TA) pIV luciferase reporter constructs have been described previously (Piskurich et al., 1999). The CIITA pIV and mIV luciferase reporter constructs were formerly called pIVCIITA.Luc and pmIRF.IVCIITA.Luc (contains the IRF-E site mutations, GAActTagAAG, with mutations designated by lowercase type). The pcDNA-PRDI-BF1 and PRDI-BF1β plasmids, which express the full-length and PRDI-BF1β isoforms respectively, have been described previously (Ghosh et al., 2001, Gyory et al., 2003). The pBJ-neo-Blimp-1 plasmids, kindly provided by Dr. K. Calame, have also been described previously (Lin et al., 1997).
The PRDI-BF1 and PRD-BF1β proteins were generated using the TnT Quick Coupled Transcription/Translation System (Promega) according to the manufacturer’s specifications. Briefly, 1 μg of plasmid DNA, 40 μl of TnT Quick Mix and 2 μl of methionine were mixed, and the total volume was adjusted to 50 μl with nuclease-free water. The mixture was incubated at 30 C for 90 min. The pcDNA3.1 vector plasmid (Invitrogen) was used as a negative control.
Raji cells were transiently transfected by electroporation and luciferase assays were performed as previously described (Piskurich et al., 1998) with the following modification: 6 h after electroporation, cells were treated with human recombinant IFN-γ (500 U/ml) for 24 h and then harvested. For all transfection experiments, co-transfections were also performed with the pGL2-Basic plasmid (Promega) as a luciferase reporter negative control. No induction or repression of this plasmid was observed. Luciferase activity was measured using a Tropix TR717 luminometer (PE Applied Biosystems); as an internal control, each transfection included 300 ng of the pRL-TK Vector (Promega), which directs the expression of Renilla luciferase. Renilla luciferase activity was measured using the Renilla Luciferase Assay System (Promega) according to the manufacturer’s protocol and used to normalize the luciferase activity for transfection efficiency.
Nuclear extracts were prepared from 2 × 106 cells according to the manufacturer’s directions using NE-PER® Nuclear and Cytoplasmic Extraction Reagents (Pierce). The WT CIITA pIV oligonucleotide probe was as follows: 5′-CTGCAGAAAGAAAGTGAAAGGGAAAAAGAACT-3′. EMSAs were performed as previously described with the following modifications: EMSAs using antibodies were performed in a reaction mixture that contained 50 mM KCl, 5 mM NaCl, 5% glycerol, 10 mM Tris (pH 7.9), 1.5 mM MgCl2, 1 mM dithiothreitol, and 3 μg of poly (dI)(dC) (Piskurich et al., 1999); EMSAs using cold competitors were performed in a reaction mixture contained 80 mM NaCl, 10% glycerol, 20 mM Tris (pH 7.5) and 0.5 μg of sheared salmon sperm DNA (Invitrogen) (Piskurich et al., 2000). Antibodies were incubated with nuclear extract or in vitro translated proteins in the reaction mixture for 30 min before addition of probe. The antibody to Blimp-1, which recognizes both the full-length and truncated forms of PRDI-BF1, and isotope control antibody were purchased from Novus. Antibodies to IRF-1 and IRF-2 were purchased from Santa Cruz Biotechnology. Oligonucleotide probes used in 200-fold molar excess as cold competitors were the Blimp-1-binding site of the c-Myc promoter, MYC, 5′-CGCGTACAGAAAGGGAAAGGACTAG-3′; CIITA pIV containing a mutation in the IRF-E site that disrupts both GAAAG sequence motifs, MUT CIITA pIV, 5′-CTGCAGAAAGAActTagAAGGGAAAAAGAACT-3′ (mutations shown in lowercase type); CIITA pIV containing a mutation in the 5′ GAAAG sequence motif, 5′MUT CIITA pIV, 5′-CTGCAGAAAGAActTGAAAGGGAAAAAGAACT-3′; CIITA pIV containing a mutation in the 3′ GAAAG sequence motif, 3′MUT CIITA pIV, 5′-CTGCAGAAAGAAAGTagAAGGGAAAAAGAACT-3′.
The dimethyl sulfate (DMS) treatment, genomic DNA preparation, amplification of human CIITA (MHC2TA) pIV using ligation-mediated PCR, electrophoresis and visualization were performed as previously described (Piskurich et al., 1999). Three MHC2TA locus-specific primers were used to amplify cleaved fragments from the upper (coding) strand of CIITA pIV. Ligation-mediated PCR was also performed on the lower (noncoding) strand, but no significant protections or enhancements were observed.
Recent evidence indicates that the PRDI-BF1/Blimp-1 DNA recognition sequence resembles the IRF-E sequences found in genes regulated by IRF-1 and IRF-2 (Kuo et al., 2004). To determine if the IRF-E site of the type IV promoter of the human CIITA gene (MHC2TA) is bound by PRDI-BF1, electrophoretic mobility shift analyses (EMSAs) were performed using nuclear extract from U266 myeloma cells that express PRDI-BF1 and a probe that spans sequences of the IRF-E site (from −77 to −30) of CIITA pIV. Multiple protein/DNA complexes were observed (Fig. 1A). To determine if these complexes contain PRDI-BF1, nuclear extracts were pre-incubated with a monoclonal antibody directed against Blimp-1 that is cross reactive with PRDI-BF1. Pre-incubation with this antibody clearly detected PRDI-BF1 within the complexes (Fig. 1A) (lane 3, asterisk). Consistent with the absence of IFN-γ stimulation, antibodies directed against IRF-1 or IRF-2 did not detect the presence of these factors within the complexes. To determine if PRDI-BF1 can directly bind to CIITA pIV, EMSAs were performed using recombinant PRDI-BF1 protein. As shown in Figure 1B, a single strong complex was formed. Specific cold competitors consisting of the wild-type CIITA pIV (WT) or of the known Blimp-1 binding site of the c-Myc promoter (MYC) diminish the formation of this complex (Fig. 1B, compare lane 1 with lanes 2 and 4). In contrast, it is not competed by a CIITA pIV competitor oligonucleotide with a site-specific mutation of the IRF-E site that disrupts both GAAAG sequence motifs (MUT) (compare lanes 1 and 3), which indicates that this complex is specific for the IRF-E. Lower faint bands are produced by truncated products in the in vitro translated PRDI-BF1 preparation. Similar results were seen in EMSAs using nuclear extracts from human U266 or NCI-H929 human myeloma cells (data not shown). These experiments demonstrate that PRDI-BF1 directly recognizes and binds to the IRF-E site of CIITA pIV.
To functionally test whether CIITA pIV is repressed by PRDI-BF1, Raji human B cells were co-transfected by electroporation with a reporter plasmid where luciferase expression was under the control of CIITA pIV and a PRDI-BF1 expression plasmid. Ectopic expression of PRDI-BF1 repressed both the basal and IFN-γ-induced activity of CIITA pIV in B lymphocytes (Fig. 2A). Ectopic expression of PRDI-BF1 resulted in a 3–8 fold suppression (3.6-fold and 4.2-fold, respectively, for the representative experiment that is shown) of both basal and IFN-γ-inducible CIITA pIV activity. IFN-γ treatment resulted in over 2-fold induction of CIITA pIV activity for co-transfections with either the vector control plasmid or the PRDI-BF1 expression plasmid.
Previous studies for the human CIITA type III promoter indicate that it is functionally repressed across species by both the human, PRDI-BF1, and the murine, Blimp-1, forms of the repressor (Piskurich et al., 2000). To determine if this is the case for the type IV promoter, co-transfections of Raji cells were performed using the CIITA pIV luciferase reporter plasmid and an expression plasmid for Blimp-1. Consistent with the finding for PRDI-BF1, a similar fold induction of CIITA pIV activity by IFN-γ was observed for both the control and Blimp-1 expression plasmids (Fig. 2B). In addition, Blimp-1 over expression resulted in suppression of basal and inducible CIITA pIV activity, comparable to the suppression seen with PRDI-BF1. These results demonstrate that, like CIITA pIII, CIITA pIV is repressed by both the human and murine forms of this repressor in B lymphocytes.
EMSA binding competition experiments performed with a CIITA pIV oligonucleotide containing a mutated IRF-E site did not diminish the specific complex that was formed using a wild-type CIITA pIV probe (Fig. 1B). To functionally determine if this IRF-E site is required for the repression of CIITA pIV by PRDI-BF1, Raji B cells were co-transfected with a PRDI-BF1 expression plasmid and a CIITA pIV luciferase reporter plasmid with an identical mutation of the IRF-E site. Ectopic expression of PRDI-BF1 did not result in a change in the basal or inducible activity of this mutated CIITA promoter (Fig. 3A). The activity of the wild-type CIITA pIV reporter plasmid is shown for comparison. We have previously shown in both B cells and 2fTGH fibrosarcoma cells that IFN-γ does not induce the activity of this mutated promoter and that the basal level of activity is lower compared to the wild-type promoter (Piskurich et al., 2005, and data not shown). These experiments provide additional support for the idea that PRDI-BF1 represses the activity of CIITA pIV by binding to sequences contained in the IRF-E site of this promoter.
Only a handful of gene targets for repression by PRDI-BF1/Blimp-1 have been verified (Kelly et al., 1991; Lin et al., 1997; Lin et al., 2002; Shaffer et al., 2002). Analysis of the promoter sequences of these genes and extensive binding analyses aimed at determining the consensus DNA-binding site for Blimp-1 indicate that this site resembles the IRF-E and contains a GAAAG sequence motif, except in the unique case of CIITA pIII (Kuo and Calame, 2004). The CIITA pIV IRF-E sequence, GAAAGTGAAAG, contains two GAAAG motifs. The IRF-E mutation used in the EMSAs and transfections described in this report so far disrupted both of these motifs. To further study the mechanism by which PRDI-BF1 regulates CIITA pIV, EMSA binding competition analyses were performed to determine which of the GAAAG motifs function in the binding of CIITA pIV by PRDI-BF1. These experiments used wild-type CIITA pIV as probe and in vitro translated PRDI-BF1 protein (Fig. 3B). The effects of specific cold competitors consisting of the CIITA pIV IRF-E site with mutations in both GAAAG motifs (MUT), or the CIITA pIV IRF-E site with a mutation in either the first (5′MUT) or second (3′MUT) motif were compared. Each of the oligonucleotides with a single mutated GAAAG motif is capable of diminishing the formation of a specific complex (Fig. 3B, compare lanes 3 and 4 with lanes 1 and 2). No additional reduction was seen when both mutated oligonucleotides were used in combination as competitors (compare lane 5 with lanes 3 and 4). These results provide additional support that the IRF-E site is required for binding and repression of CIITA pIV by PRDI-BF1 and demonstrate that both GAAAG motifs can participate in the binding of this repressor.
In vivo genomic footprinting is the method of choice to identify physiologically relevant sequences within a small region of DNA such as the region surrounding the CIITA pIV IRF-E. DMS-treated genomic DNA was obtained from U266 myeloma cells and CA46 B cells. Significant protections indicating protein-DNA contacts were observed in U266 myeloma cells at both GAAAG sequence motifs in the IRF-E site (Fig. 4). These protections were not observed in cells that do not express PRDI-BF1 including Raji and CA 46 B cells (Piskurich et al., 2005, and data not shown). These findings are consistent with PRDI-BF1 binding to the CIITA pIV IRF-E in myeloma cells and lend support to the notion that both GAAAG motifs can participate in the binding of this repressor.
An alternative protein product was recently described for the PRDI-BF1 gene, PRDM1 (Gyory et al., 2003). In addition to the full-length form of PRDI-BF1, myeloma cells co-express a protein isoform called PRDI-BF1β that arises from initiation of the transcription of this gene at an alternative site. Compared to the originally described full-length form of PRDI-BF1, the PRDI-BF1β isoform lacks 101 amino acids at the amino-terminus but retains the zinc finger DNA binding motif of this protein. To examine the ability of this isoform to bind CIITA pIV, EMSAs were performed using CIITA pIV as probe and in vitro translated PRDI-BF1β protein. One predominant complex was shifted by pre-incubation with anti-Blimp-1, which recognizes an epitope that is conserved in PRDI-BF1β (Fig. 5A) (lane 3, asterisk). The incomplete shifting of this band reflects the activity of the antibody to Blimp-1 and also occurs with the full-length form of PRDI-BF1. The wild-type CIITA pIV oligonucleotide (WT, lane 2) and an oligonucleotide bearing the Blimp-1 binding site of the c-Myc gene promoter (MYC, lane 4) greatly reduced this complex, while a CIITA pIV oligonucleotide bearing a mutated IRF-E did not (MUT, lane 3) (Fig. 5B). Oligonucleotides with mutations that disrupt either the first or second GAAAG motif also reduced this complex (Fig. 5C). These results demonstrate that the PRDI-BF1β isoform has a similar binding interaction with CIITA pIV compared to full-length PRDI-BF1.
PRDI-BF1β does not act as a classical transdominant repressor of PRDI-BF1 and has actually been shown to retain about 50% of the ability to repress CIITA pIII, and 72% of the ability to repress the c-Myc promoter compared to the full-length protein (Gyory et al., 2003). To determine the ability of PRD-BF1β to repress CIITA pIV, co-transfections were performed in Raji B cells using plasmids expressing either the PRDI-BF1 full-length or β-form, and the CIITA pIV luciferase reporter plasmid. PRD-BF1β exhibits a similar ability to repress CIITA pIV compared to the full-length protein (Fig. 6). Taken together, the EMSA and promoter analyses demonstrate that the PRD-BF1β form of PRDI-BF1 binds and potentially represses CIITA pIV activity in myeloma cells.
MHC class II genes encode proteins involved in the presentation of antigenic peptides to CD4+ T lymphocytes and therefore play a central role in immune responses. CIITA is of crucial importance for the regulation of the expression of MHC class II genes at the level of transcription. As such, its expression is a major factor in the control of antigen presentation (van den Elsen et al., 2004). The expression pattern of the CIITA gene reflects this important role. Constitutive expression is confined to professional antigen presenting cells like B lymphocytes and dendritic cells (Muhlethaler-Mottet et al., 1997). For instance, the CIITA type III promoter is constitutively active in B lymphocytes. CIITA expression is also inducible by IFN-γ in other cell types. Although CIITA pIII activity can be induced by IFN-γ, much of the inducible expression of CIITA occurs through induction of the CIITA type IV promoter and we have recently shown this to be the case for B cells (Piskurich et al., 2006).
CIITA expression is also under developmental control. For example, its expression is silenced when B cells differentiate into plasma cells (Latron et al., 1988; Dellabona et al., 1989; Sartoris et al., 1996). PRDI-BF1, a transcriptional repressor that triggers the terminal differentiation of B cells into plasma cells, is expressed in multiple myeloma cells (Turner, Jr. et al., 1994; Shaffer et al., 2002). We have previously shown that PRDI-BF1 suppresses CIITA expression by repressing the constitutive activity of the CIITA type III promoter in B lymphocytes and myeloma cells (Piskurich et al., 2000; Ghosh et al., 2001). Since they generally express low levels of MHC class II proteins, it is possible that multiple myeloma cells and plasmacytoma cells escape the immune system by suppressing the CIITA expression (Liu et al., 1999; Walter et al., 2000; Prod’homme et al., 2004). For this reason, we have been interested in studying the ways in which CIITA expression is controlled in the B lymphocyte lineage. In this study, we demonstrate for the first time that PRDI-BF1 suppresses the activity of the CIITA type IV promoter. This finding lends new support to the idea that PRDI-BF1 is a key factor in the control of CIITA expression in B lymphocytes and myeloma cells.
A recent report identified a consensus site for the binding of Blimp-1, the murine homolog of PRDI-BF1, using random oligonucleotide selection (Kuo and Calame, 2004). It concluded that the binding site for this repressor resembles an IRF-E site, but that Blimp-1 does not bind all IRF-Es. It also suggested that the GAAAG sequence motif was important for repressor binding. The DNA sequence of the IRF-E of the CIITA type IV promoter, GAAAGTGAAAG, contains two GAAAG sequence motifs. When both of these motifs are mutated, activation of this promoter by IFN-γ and its ability to be bound and suppressed by PRDI-BF1 is severely diminished. We further demonstrate that the GAAAG motifs within this IRF-E can participate in PRDI-BF1 binding. These data provide new support for the idea that PRDI-BF1 binds IRF-E sites that contain the GAAAG motif. These findings provide knowledge that may assist in the identification of novel gene targets for repression by PRDI-BF1/Blimp-1. While PRDI-BF1 suppresses both the basal and IFN-γ-induced activity of the CIITA type IV promoter, some induction of this promoter by IFN-γ is retained. Importantly, this finding demonstrates that it may still be possible to therapeutically up regulate the activity of the CIITA type IV promoter and MHC II expression in myeloma cells using IFN-γ.
PRDI-BF1 belongs the PRDM family of proteins. Unifying features of this family are that they all function as transcriptional repressors and contain a PR domain, although the exact function of this domain is unknown (Keller and Maniatis, 1991; Alvarez-Venegas and Avramova, 2002). Elevated expression of truncated isoforms of PRDM proteins, lacking the PR domain and amino terminus of the protein, have been demonstrated in some types of neoplastic cells and may play a role in disease (Schneider et al., 2002). A truncated isoform of PRDI-BF1 was recently described (Gyory et al., 2003). This isoform, called PRDI-BF1β, is 101 amino acids shorter, lacks the amino-terminal acidic domain and contains an incomplete PR domain compared to full-length PRDI-BF1. Myeloma cells co-express both the full-length PRDI-BF1 and PRDI-BF1β forms. PRDI-BF1β represses the CIITA (MHCIITA) type III and c-Myc promoters, but this suppression is 25–50% less than full-length PRDI-BF1. We now demonstrate that the PRDI-BF1β isoform binds to the CIITA type IV promoter and its ability to repress CIITA pIV is not impaired. These results suggest that the amino-terminal acidic and PR domains do not play an important role in the suppression of the CIITA type IV promoter and are consistent with the previous finding that PRDI-BF1β does not act as a classical transdominant negative of PRDI-BF1.
In summary, we have investigated the ability of the transcriptional repressor, PRDI-BF1/Blimp-1, to suppress the CIITA type IV promoter in B lymphocytes. Our results indicate that this promoter is bound and suppressed by PRDI-BF1. Binding and suppression are dependent on the IRF-E site of CIITA pIV. These findings provide new evidence that PRDI-BF1 is a key factor in the control of CIITA expression in the B lymphocyte lineage. CIITA controls the expression of MHC class II genes that are required for the recognition of antigens by the immune system. Knowledge of the ways in which it is controlled in myeloma cells may prove useful in the design of therapies aimed at increasing the ability of the immune system to recognize B cell neoplasms, especially multiple myeloma.
The authors wish to thank Kathryn Calame for providing the pBJ-neo-Blimp-1 and control plasmids. This investigation was supported in part by research grants from the National Cancer Institute (RO1CA102203 and RO1CA114504) and the MEDCEN Community Health Foundation of Central Georgia.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.